Influence of nuclear physics inputs and astrophysical conditions on Th/U chronometer

The productions of thorium and uranium are key ingredients in $r$-process nucleo-cosmochronology. With the combination of improved nuclear and stellar data, we have made detailed investigations on the $r$-process abundance pattern in the very metal-poor halo stars based on the classical $r$-process approach. It is found that the results are almost independent of specified simulations to observed abundances. The influence from nuclear mass uncertainties on Th/U chronometer can approach 2 Gyr. Moreover, the ages of the metal-poor stars HE 1523-0901, CS 31082-001, and BD +17$^\circ$3248 are determined as $11.8\pm 3.7$, $13.5\pm 2.9$, and $10.9 \pm 2.9$ Gyr, respectively. The results can serve as an independent check for age estimate of the universe.Comment: 20 pages, 5 figures. accepted by Phys. Rev.

Feasibility of the finite amplitude method in covariant density functional theory

Self-consistent relativistic random-phase approximation (RPA) in the radial coordinate representation is established by using the finite amplitude method (FAM). Taking the isoscalar giant monopole resonance in spherical nuclei as example, the feasibility of the FAM for the covariant density functionals is demonstrated, and the newly developed methods are verified by the conventional RPA calculations. In the present relativistic RPA calculations, the effects of the Dirac sea can be automatically taken into account in the coordinate-space representation. The rearrangement terms due to the density-dependent couplings can be implicitly calculated without extra computational costs in both iterative and matrix FAM schemes.Comment: 12 pages, 5 figure

Finite-amplitude method: An extension to the covariant density functionals

The finite-amplitude method (FAM) is one of the most promising methods for optimizing the computational performance of the random-phase approximation (RPA) calculations in deformed nuclei. In this report, we will mainly focus on our recent progress in the self-consistent relativistic RPA established by using the FAM. It is found that the effects of Dirac sea can be taken into account implicitly in the coordinate-space representation and the rearrangement terms due to the density-dependent couplings can be treated without extra computational costs.Comment: 5 pages, 2 figures, Proceedings of the 20th Nuclear Physics Workshop "Marie & Pierre Curie", Kazimierz, Poland, 25-29 September, 201

Nuclear mass table in deformed relativistic Hartree-Bogoliubov theory in continuum, II: Even-ZZ nuclei

The mass table in the deformed relativistic Hartree-Bogoliubov theory in continuum (DRHBc) with the PC-PK1 density functional has been established for even-$Z$ nuclei with $8\le Z\le120$, extended from the previous work for even-even nuclei [Zhang $\it{et.~al.}$ (DRHBc Mass Table Collaboration), At. Data Nucl. Data Tables 144, 101488 (2022)]. The calculated binding energies, two-nucleon and one-neutron separation energies, root-mean-square (rms) radii of neutron, proton, matter, and charge distributions, quadrupole deformations, and neutron and proton Fermi surfaces are tabulated and compared with available experimental data. A total of 4829 even-$Z$ nuclei are predicted to be bound, with an rms deviation of 1.477 MeV from the 1244 mass data. Good agreement with the available experimental odd-even mass differences, $\alpha$ decay energies, and charge radii is also achieved. The description accuracy for nuclear masses and nucleon separation energies as well as the prediction for drip lines is compared with the results obtained from other relativistic and nonrelativistic density functional. The comparison shows that the DRHBc theory with PC-PK1 provides an excellent microscopic description for the masses of even-$Z$ nuclei. The systematics of the nucleon separation energies, odd-even mass differences, pairing energies, two-nucleon gaps, $\alpha$ decay energies, rms radii, quadrupole deformations, potential energy curves, neutron density distributions, and neutron mean-field potentials are discussed.Comment: 394 pages, 17 figures, 2 tables, published in Atomic Data and Nuclear Data Tables, data file in the TXT form is available for download under "Ancillary files

Sex differences in oncogenic mutational processes.

Sex differences have been observed in multiple facets of cancer epidemiology, treatment and biology, and in most cancers outside the sex organs. Efforts to link these clinical differences to specific molecular features have focused on somatic mutations within the coding regions of the genome. Here we report a pan-cancer analysis of sex differences in whole genomes of 1983 tumours of 28 subtypes as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium. We both confirm the results of exome studies, and also uncover previously undescribed sex differences. These include sex-biases in coding and non-coding cancer drivers, mutation prevalence and strikingly, in mutational signatures related to underlying mutational processes. These results underline the pervasiveness of molecular sex differences and strengthen the call for increased consideration of sex in molecular cancer research

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke

Importance It is uncertain whether intravenous methylprednisolone improves outcomes for patients with acute ischemic stroke due to large-vessel occlusion (LVO) undergoing endovascular thrombectomy. Objective To assess the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for acute ischemic stroke secondary to LVO. Design, Setting, and Participants This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 82 hospitals in China, enrolling 1680 patients with stroke and proximal intracranial LVO presenting within 24 hours of time last known to be well. Recruitment took place between February 9, 2022, and June 30, 2023, with a final follow-up on September 30, 2023.InterventionsEligible patients were randomly assigned to intravenous methylprednisolone (n = 839) at 2 mg/kg/d or placebo (n = 841) for 3 days adjunctive to endovascular thrombectomy. Main Outcomes and Measures The primary efficacy outcome was disability level at 90 days as measured by the overall distribution of the modified Rankin Scale scores (range, 0 [no symptoms] to 6 [death]). The primary safety outcomes included mortality at 90 days and the incidence of symptomatic intracranial hemorrhage within 48 hours. Results Among 1680 patients randomized (median age, 69 years; 727 female [43.3%]), 1673 (99.6%) completed the trial. The median 90-day modified Rankin Scale score was 3 (IQR, 1-5) in the methylprednisolone group vs 3 (IQR, 1-6) in the placebo group (adjusted generalized odds ratio for a lower level of disability, 1.10 [95% CI, 0.96-1.25]; P = .17). In the methylprednisolone group, there was a lower mortality rate (23.2% vs 28.5%; adjusted risk ratio, 0.84 [95% CI, 0.71-0.98]; P = .03) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%; adjusted risk ratio, 0.74 [95% CI, 0.55-0.99]; P = .04) compared with placebo. Conclusions and Relevance Among patients with acute ischemic stroke due to LVO undergoing endovascular thrombectomy, adjunctive methylprednisolone added to endovascular thrombectomy did not significantly improve the degree of overall disability.Trial RegistrationChiCTR.org.cn Identifier: ChiCTR210005172

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Funder: NCI U24CA211006Abstract: The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts